Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: March 2, 2026, 11:19 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 532331 | NSE: AJANTPHARM

Ajanta Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: March 2, 2026, 11:19 am

Market Cap 37,078 Cr.
Current Price 2,968
Intrinsic Value₹2,753.47
High / Low 3,054/2,022
Stock P/E36.5
Book Value 345
Dividend Yield0.96 %
ROCE32.4 %
ROE24.9 %
Face Value 2.00
PEG Ratio4.64

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Ajanta Pharma Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Ajanta Pharma Ltd 37,078 Cr. 2,968 3,054/2,02236.5 3450.96 %32.4 %24.9 % 2.00
Ipca Laboratories Ltd 38,523 Cr. 1,518 1,595/1,16836.5 2930.26 %14.7 %12.8 % 1.00
J B Chemicals & Pharmaceuticals Ltd 33,220 Cr. 2,069 2,115/1,30344.1 2430.76 %25.8 %20.1 % 1.00
Glaxosmithkline Pharmaceuticals Ltd 43,164 Cr. 2,548 3,516/2,22042.9 1011.61 %63.2 %46.9 % 10.0
Gland Pharma Ltd 29,204 Cr. 1,773 2,131/1,20024.6 6101.01 %15.8 %11.6 % 1.00
Industry Average20,397.81 Cr1,087.5754.93201.210.38%16.35%15.16%6.10

All Competitor Stocks of Ajanta Pharma Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 9728821,0211,0281,1051,0541,1451,1871,1461,1701,3031,3541,375
Expenses 8027327507387917768158758258739511,026993
Operating Profit 170149271291314278330311321297351328382
OPM % 17%17%27%28%28%26%29%26%28%25%27%24%28%
Other Income 35373221143626193018265925
Interest 3112221686535
Depreciation 33333334343434343640414344
Profit before tax 168152269276291278322290307269331341359
Tax % 20%20%23%29%28%27%24%25%24%16%23%24%24%
Net Profit 135122208195210203246216233225255260274
EPS in Rs 10.509.5416.2415.2416.3915.8219.6817.3318.6418.0320.4420.8321.91

Last Updated: February 6, 2026, 8:17 pm

Below is a detailed analysis of the quarterly data for Ajanta Pharma Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

  • For Sales, as of Dec 2025, the value is 1,375.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,354.00 Cr. (Sep 2025) to 1,375.00 Cr., marking an increase of 21.00 Cr..
  • For Expenses, as of Dec 2025, the value is 993.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,026.00 Cr. (Sep 2025) to 993.00 Cr., marking a decrease of 33.00 Cr..
  • For Operating Profit, as of Dec 2025, the value is 382.00 Cr.. The value appears strong and on an upward trend. It has increased from 328.00 Cr. (Sep 2025) to 382.00 Cr., marking an increase of 54.00 Cr..
  • For OPM %, as of Dec 2025, the value is 28.00%. The value appears strong and on an upward trend. It has increased from 24.00% (Sep 2025) to 28.00%, marking an increase of 4.00%.
  • For Other Income, as of Dec 2025, the value is 25.00 Cr.. The value appears to be declining and may need further review. It has decreased from 59.00 Cr. (Sep 2025) to 25.00 Cr., marking a decrease of 34.00 Cr..
  • For Interest, as of Dec 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Sep 2025) to 5.00 Cr., marking an increase of 2.00 Cr..
  • For Depreciation, as of Dec 2025, the value is 44.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 43.00 Cr. (Sep 2025) to 44.00 Cr., marking an increase of 1.00 Cr..
  • For Profit before tax, as of Dec 2025, the value is 359.00 Cr.. The value appears strong and on an upward trend. It has increased from 341.00 Cr. (Sep 2025) to 359.00 Cr., marking an increase of 18.00 Cr..
  • For Tax %, as of Dec 2025, the value is 24.00%. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 24.00%.
  • For Net Profit, as of Dec 2025, the value is 274.00 Cr.. The value appears strong and on an upward trend. It has increased from 260.00 Cr. (Sep 2025) to 274.00 Cr., marking an increase of 14.00 Cr..
  • For EPS in Rs, as of Dec 2025, the value is 21.91. The value appears strong and on an upward trend. It has increased from 20.83 (Sep 2025) to 21.91, marking an increase of 1.08.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 18, 2026, 6:01 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1,2081,4741,7491,9832,1262,0552,5882,8903,3413,7434,2094,6485,202
Expenses 8409681,1551,2921,4671,4891,9041,8892,4082,9343,0373,3793,843
Operating Profit 3695055946916585676831,0019338081,1721,2691,359
OPM % 31%34%34%35%31%28%26%35%28%22%28%27%26%
Other Income 148142024218824112748585129
Interest 96510112810672120
Depreciation 44524461607296116125131135144168
Profit before tax 3304565596486235146649009097451,1141,1891,300
Tax % 29%32%26%22%25%25%30%27%22%21%27%23%
Net Profit 2343104165074693874686547135888169201,015
EPS in Rs 17.7523.4731.4938.4035.5029.5635.7350.3855.6345.8963.7073.6881.21
Dividend Payout % 15%17%17%23%0%20%24%13%11%15%79%38%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)32.48%34.19%21.88%-7.50%-17.48%20.93%39.74%9.02%-17.53%38.78%12.75%
Change in YoY Net Profit Growth (%)0.00%1.71%-12.32%-29.37%-9.99%38.41%18.81%-30.72%-26.55%56.31%-26.03%

Ajanta Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:12%
5 Years:12%
3 Years:12%
TTM:11%
Compounded Profit Growth
10 Years:11%
5 Years:14%
3 Years:9%
TTM:9%
Stock Price CAGR
10 Years:11%
5 Years:21%
3 Years:25%
1 Year:-19%
Return on Equity
10 Years:24%
5 Years:22%
3 Years:22%
Last Year:25%

Last Updated: September 4, 2025, 10:30 pm

Balance Sheet

Last Updated: December 4, 2025, 12:55 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 18181818181818171725252525
Reserves 5768231,1731,5502,0242,2282,5812,9783,2473,3633,5423,7654,290
Borrowings 13072811236753125363547246
Other Liabilities 2262332072543833836197027111,1599271,0671,112
Total Liabilities 9491,1461,4791,8232,4262,6643,2933,7294,0004,5824,5304,9045,672
Fixed Assets 2792884515891,0531,1781,4721,5411,5121,4961,4791,7621,873
CWIP 9417024033961262132108153209256176146
Investments 6360861821907879176147535349464874
Other Assets 5136297037131,1221,1471,6101,9042,1882,3412,4462,5022,779
Total Assets 9491,1461,4791,8232,4262,6643,2933,7294,0004,5824,5304,9045,672

Below is a detailed analysis of the balance sheet data for Ajanta Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
  • For Reserves, as of Sep 2025, the value is 4,290.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,765.00 Cr. (Mar 2025) to 4,290.00 Cr., marking an increase of 525.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 246.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 47.00 Cr. (Mar 2025) to 246.00 Cr., marking an increase of 199.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 1,112.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,067.00 Cr. (Mar 2025) to 1,112.00 Cr., marking an increase of 45.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 5,672.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,904.00 Cr. (Mar 2025) to 5,672.00 Cr., marking an increase of 768.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 1,873.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,762.00 Cr. (Mar 2025) to 1,873.00 Cr., marking an increase of 111.00 Cr..
  • For CWIP, as of Sep 2025, the value is 146.00 Cr.. The value appears to be declining and may need further review. It has decreased from 176.00 Cr. (Mar 2025) to 146.00 Cr., marking a decrease of 30.00 Cr..
  • For Investments, as of Sep 2025, the value is 874.00 Cr.. The value appears strong and on an upward trend. It has increased from 464.00 Cr. (Mar 2025) to 874.00 Cr., marking an increase of 410.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 2,779.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,502.00 Cr. (Mar 2025) to 2,779.00 Cr., marking an increase of 277.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 5,672.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,904.00 Cr. (Mar 2025) to 5,672.00 Cr., marking an increase of 768.00 Cr..

Notably, the Reserves (4,290.00 Cr.) exceed the Borrowings (246.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 2122793266092813754575765627927851,157
Cash from Investing Activity + -188-158-209-383-256-223-224-282-74-56065-377
Cash from Financing Activity + -20-105-117-202-0-147-129-318-460-108-1,051-733
Net Cash Flow 416-024254104-2428124-20147

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow239.00433.00513.00690.00656.00531.00608.00-30.00908.00772.00-34.00-46.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 6164785979821099311110310893
Inventory Days 164159180186315415276434347283283308
Days Payable 132109128157224214202212143147159155
Cash Conversion Cycle 9411413088170282184315315240233246
Working Capital Days 395678651031131081261408311997
ROCE %55%57%52%46%34%24%27%32%29%23%32%32%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 66.11%66.22%66.22%66.22%66.22%66.27%66.26%66.26%66.26%66.26%66.25%66.25%
FIIs 10.00%10.19%9.99%9.11%8.54%8.36%9.11%9.26%8.86%8.86%8.53%7.97%
DIIs 15.52%15.36%15.60%16.67%17.48%17.41%17.09%17.02%17.48%17.50%17.90%18.58%
Government 0.45%0.46%0.00%0.00%0.00%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public 7.91%7.78%8.21%8.00%7.76%7.94%7.51%7.45%7.38%7.38%7.32%7.20%
No. of Shareholders 83,54954,87456,27754,35155,48870,31664,31566,89670,82768,88267,78565,409

Shareholding Pattern Chart

No. of Shareholders

Ajanta Pharma Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Small Cap Fund 1,674,471 0.71 465.821,977,7442025-12-08 07:42:13-15.33%
UTI Flexi Cap Fund 1,414,000 1.67 393.361,425,0002026-01-25 06:31:44-0.77%
Kotak Small Cap Fund 1,219,302 2.07 339.2N/AN/AN/A
Nippon India Pharma Fund 959,323 3.39 266.87968,2142025-12-08 04:19:42-0.92%
HDFC Large and Mid Cap Fund 897,224 0.88 249.6N/AN/AN/A
Canara Robeco Large and Mid Cap Fund 877,439 0.99 244.09878,5062026-02-23 01:29:43-0.12%
UTI Mid Cap Fund 831,388 2.01 231.28836,3882026-02-23 01:29:43-0.6%
Nippon India Multi Cap Fund 807,460 0.46 224.63628,9662025-12-08 02:19:2728.38%
Canara Robeco Small Cap Fund 747,040 1.64 207.82698,0372026-02-23 01:29:437.02%
Kotak Large & Midcap Fund 500,000 0.46 139.1N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 73.5664.8245.8982.4575.09
Diluted EPS (Rs.) 73.5364.7745.8982.4575.09
Cash EPS (Rs.) 84.9275.3156.8997.6188.55
Book Value[Excl.RevalReserv]/Share (Rs.) 302.38282.34268.14380.24344.52
Book Value[Incl.RevalReserv]/Share (Rs.) 302.38282.34268.14380.24344.52
Revenue From Operations / Share (Rs.) 370.81333.10296.21389.17332.34
PBDIT / Share (Rs.) 108.0299.4569.80121.72117.83
PBIT / Share (Rs.) 96.5288.7359.45107.13104.48
PBT / Share (Rs.) 94.8788.1658.98105.94103.53
Net Profit / Share (Rs.) 73.4364.6046.5483.0175.20
NP After MI And SOA / Share (Rs.) 73.4364.6046.5483.0175.20
PBDIT Margin (%) 29.1329.8523.5631.2735.45
PBIT Margin (%) 26.0226.6320.0627.5231.43
PBT Margin (%) 25.5826.4619.9127.2231.15
Net Profit Margin (%) 19.8019.3915.7121.3322.62
NP After MI And SOA Margin (%) 19.8019.3915.7121.3322.62
Return on Networth / Equity (%) 24.2822.8717.3521.8321.82
Return on Capital Employeed (%) 30.1029.9521.2126.9829.02
Return On Assets (%) 18.3517.5912.5617.5717.30
Asset Turnover Ratio (%) 0.960.900.810.830.79
Current Ratio (X) 2.853.052.493.503.13
Quick Ratio (X) 1.952.121.772.281.94
Inventory Turnover Ratio (X) 5.371.141.191.101.25
Dividend Payout Ratio (NP) (%) 38.0078.6815.2511.5312.67
Dividend Payout Ratio (CP) (%) 32.8567.4812.479.8110.76
Earning Retention Ratio (%) 62.0021.3284.7588.4787.33
Cash Earning Retention Ratio (%) 67.1532.5287.5390.1989.24
Interest Coverage Ratio (X) 65.32174.28151.01102.45123.89
Interest Coverage Ratio (Post Tax) (X) 45.40114.20101.6870.8780.07
Enterprise Value (Cr.) 32649.2528149.1114945.6115321.6715384.30
EV / Net Operating Revenue (X) 7.026.693.994.595.32
EV / EBITDA (X) 24.1122.4016.9514.6615.02
MarketCap / Net Operating Revenue (X) 7.066.724.084.655.40
Retention Ratios (%) 61.9921.3184.7488.4687.32
Price / BV (X) 8.667.934.514.765.21
Price / Net Operating Revenue (X) 7.066.724.084.655.40
EarningsYield 0.020.020.030.040.04

After reviewing the key financial ratios for Ajanta Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 73.56. This value is within the healthy range. It has increased from 64.82 (Mar 24) to 73.56, marking an increase of 8.74.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 73.53. This value is within the healthy range. It has increased from 64.77 (Mar 24) to 73.53, marking an increase of 8.76.
  • For Cash EPS (Rs.), as of Mar 25, the value is 84.92. This value is within the healthy range. It has increased from 75.31 (Mar 24) to 84.92, marking an increase of 9.61.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 302.38. It has increased from 282.34 (Mar 24) to 302.38, marking an increase of 20.04.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 302.38. It has increased from 282.34 (Mar 24) to 302.38, marking an increase of 20.04.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 370.81. It has increased from 333.10 (Mar 24) to 370.81, marking an increase of 37.71.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 108.02. This value is within the healthy range. It has increased from 99.45 (Mar 24) to 108.02, marking an increase of 8.57.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 96.52. This value is within the healthy range. It has increased from 88.73 (Mar 24) to 96.52, marking an increase of 7.79.
  • For PBT / Share (Rs.), as of Mar 25, the value is 94.87. This value is within the healthy range. It has increased from 88.16 (Mar 24) to 94.87, marking an increase of 6.71.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 73.43. This value is within the healthy range. It has increased from 64.60 (Mar 24) to 73.43, marking an increase of 8.83.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 73.43. This value is within the healthy range. It has increased from 64.60 (Mar 24) to 73.43, marking an increase of 8.83.
  • For PBDIT Margin (%), as of Mar 25, the value is 29.13. This value is within the healthy range. It has decreased from 29.85 (Mar 24) to 29.13, marking a decrease of 0.72.
  • For PBIT Margin (%), as of Mar 25, the value is 26.02. This value exceeds the healthy maximum of 20. It has decreased from 26.63 (Mar 24) to 26.02, marking a decrease of 0.61.
  • For PBT Margin (%), as of Mar 25, the value is 25.58. This value is within the healthy range. It has decreased from 26.46 (Mar 24) to 25.58, marking a decrease of 0.88.
  • For Net Profit Margin (%), as of Mar 25, the value is 19.80. This value exceeds the healthy maximum of 10. It has increased from 19.39 (Mar 24) to 19.80, marking an increase of 0.41.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 19.80. This value is within the healthy range. It has increased from 19.39 (Mar 24) to 19.80, marking an increase of 0.41.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 24.28. This value is within the healthy range. It has increased from 22.87 (Mar 24) to 24.28, marking an increase of 1.41.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 30.10. This value is within the healthy range. It has increased from 29.95 (Mar 24) to 30.10, marking an increase of 0.15.
  • For Return On Assets (%), as of Mar 25, the value is 18.35. This value is within the healthy range. It has increased from 17.59 (Mar 24) to 18.35, marking an increase of 0.76.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.96. It has increased from 0.90 (Mar 24) to 0.96, marking an increase of 0.06.
  • For Current Ratio (X), as of Mar 25, the value is 2.85. This value is within the healthy range. It has decreased from 3.05 (Mar 24) to 2.85, marking a decrease of 0.20.
  • For Quick Ratio (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has decreased from 2.12 (Mar 24) to 1.95, marking a decrease of 0.17.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 1.14 (Mar 24) to 5.37, marking an increase of 4.23.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 38.00. This value is within the healthy range. It has decreased from 78.68 (Mar 24) to 38.00, marking a decrease of 40.68.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 32.85. This value is within the healthy range. It has decreased from 67.48 (Mar 24) to 32.85, marking a decrease of 34.63.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 62.00. This value is within the healthy range. It has increased from 21.32 (Mar 24) to 62.00, marking an increase of 40.68.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 67.15. This value is within the healthy range. It has increased from 32.52 (Mar 24) to 67.15, marking an increase of 34.63.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 65.32. This value is within the healthy range. It has decreased from 174.28 (Mar 24) to 65.32, marking a decrease of 108.96.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 45.40. This value is within the healthy range. It has decreased from 114.20 (Mar 24) to 45.40, marking a decrease of 68.80.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 32,649.25. It has increased from 28,149.11 (Mar 24) to 32,649.25, marking an increase of 4,500.14.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.02. This value exceeds the healthy maximum of 3. It has increased from 6.69 (Mar 24) to 7.02, marking an increase of 0.33.
  • For EV / EBITDA (X), as of Mar 25, the value is 24.11. This value exceeds the healthy maximum of 15. It has increased from 22.40 (Mar 24) to 24.11, marking an increase of 1.71.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.06. This value exceeds the healthy maximum of 3. It has increased from 6.72 (Mar 24) to 7.06, marking an increase of 0.34.
  • For Retention Ratios (%), as of Mar 25, the value is 61.99. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 61.99, marking an increase of 40.68.
  • For Price / BV (X), as of Mar 25, the value is 8.66. This value exceeds the healthy maximum of 3. It has increased from 7.93 (Mar 24) to 8.66, marking an increase of 0.73.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.06. This value exceeds the healthy maximum of 3. It has increased from 6.72 (Mar 24) to 7.06, marking an increase of 0.34.
  • For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Ajanta Pharma Ltd as of March 2, 2026 is: ₹2,532.51

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 2, 2026, Ajanta Pharma Ltd is Overvalued by 14.67% compared to the current share price ₹2,968.00

Intrinsic Value of Ajanta Pharma Ltd as of March 2, 2026 is: ₹2,731.56

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 2, 2026, Ajanta Pharma Ltd is Overvalued by 7.97% compared to the current share price ₹2,968.00

Last 5 Year EPS CAGR: 7.86%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 36.92%, which is a positive sign.
  2. The company has higher reserves (2,472.31 cr) compared to borrowings (62.85 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (2.38 cr) and profit (488.54 cr) over the years.
  1. The stock has a high average Working Capital Days of 93.92, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 200.92, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ajanta Pharma Ltd:
    1. Net Profit Margin: 19.8%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 30.1% (Industry Average ROCE: 16.35%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 24.28% (Industry Average ROE: 15.16%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 45.4
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.95
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 36.5 (Industry average Stock P/E: 54.93)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Ajanta Pharma Ltd. is a Public Limited Listed company incorporated on 31/12/1979 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1979PLC022059 and registration number is 022059. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 4322.04 Cr. and Equity Capital is Rs. 25.07 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsAjanta House, Charkop, Kandivli (West), Mumbai Maharashtra 400067Contact not found
Management
NamePosition Held
Mr. Mannalal B AgrawalChairman
Mr. Madhusudan B AgrawalVice Chairman
Mr. Yogesh M AgrawalManaging Director
Mr. Rajesh M AgrawalJoint Managing Director
Mr. David RasquinhaIndependent Director
Ms. Medha JoshiIndependent Director
Mr. Rajesh DalalIndependent Director
Ms. Simi ThaparIndependent Director

FAQ

What is the intrinsic value of Ajanta Pharma Ltd?

Ajanta Pharma Ltd's intrinsic value (as of 02 March 2026) is ₹2731.56 which is 7.97% lower the current market price of ₹2,968.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹37,078 Cr. market cap, FY2025-2026 high/low of ₹3,054/2,022, reserves of ₹4,290 Cr, and liabilities of ₹5,672 Cr.

What is the Market Cap of Ajanta Pharma Ltd?

The Market Cap of Ajanta Pharma Ltd is 37,078 Cr..

What is the current Stock Price of Ajanta Pharma Ltd as on 02 March 2026?

The current stock price of Ajanta Pharma Ltd as on 02 March 2026 is ₹2,968.

What is the High / Low of Ajanta Pharma Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Ajanta Pharma Ltd stocks is ₹3,054/2,022.

What is the Stock P/E of Ajanta Pharma Ltd?

The Stock P/E of Ajanta Pharma Ltd is 36.5.

What is the Book Value of Ajanta Pharma Ltd?

The Book Value of Ajanta Pharma Ltd is 345.

What is the Dividend Yield of Ajanta Pharma Ltd?

The Dividend Yield of Ajanta Pharma Ltd is 0.96 %.

What is the ROCE of Ajanta Pharma Ltd?

The ROCE of Ajanta Pharma Ltd is 32.4 %.

What is the ROE of Ajanta Pharma Ltd?

The ROE of Ajanta Pharma Ltd is 24.9 %.

What is the Face Value of Ajanta Pharma Ltd?

The Face Value of Ajanta Pharma Ltd is 2.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Ajanta Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports